FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion

Pirtobrutinib wins FDA approval for frontline CLL/SLL treatment

The FDA expanded approval of pirtobrutinib, a non-covalent BTK inhibitor, for chronic lymphocytic leukemia and small lymphocytic lymphoma in the frontline setting.